By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Incyte Corporation 

Experimental Station
Route 141 & Henry Clay Road, Building E336
Wilmington  Delaware  19880  U.S.A.
Phone: 302-498-6700 Fax: 302-425-2750


Company News
Incyte Corporation (INCY)'s Jakafi Fails to Provide RELIEF In Phase 3 Trial 7/24/2014 1:00:44 PM
Incyte Corporation (INCY) To Report Second Quarter 2014 Financial Results On July 31 7/14/2014 10:26:55 AM
Incyte Corporation (INCY) Grabs $25 Million Milestone From Novartis AG (NVS) 7/8/2014 10:02:31 AM
Incyte Corporation (INCY) To Present At The 9th Annual JMP Securities Healthcare Conference 6/12/2014 8:46:18 AM
Incyte Corporation (INCY) Release: Pivotal Phase 3 Data In Polycythemia Vera Show That Jakafi® (Ruxolitinib) Achieved Superior Disease Control Compared To Best Available Therapies 6/3/2014 10:06:43 AM
Incyte Corporation (INCY) Announces Full Results From Proof-Of-Concept Phase II RECAP Trial Of Jakafi® (Ruxolitinib) In Combination With Capecitabine In Patients With Metastatic Pancreatic Cancer 6/3/2014 8:36:21 AM
Bristol-Myers Squibb Company (BMY) On A Roll, Strikes Second Clinical Immunotherapy Pact With Incyte Corporation (INCY); Incyte Stock Up 3.41% At 9:43AM On Tuesday 5/27/2014 6:54:57 AM
Incyte Corporation (INCY) To Present At Upcoming Investor Conferences 5/20/2014 6:57:36 AM
Incyte Corporation (INCY) And MedImmune (AZN) Announce Collaboration On Immuno-Oncology Combination Clinical Trial 5/14/2014 9:08:57 AM
Incyte Corporation (INCY) To Present At Upcoming Investor Conferences 5/2/2014 9:46:36 AM